Empowered Funds LLC raised its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 142.2% during

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercep

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the ana

LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Compan

ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safet

LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS

ITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.

LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Compan

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early huma

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans,

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company adva

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.21 per share versus the Zacks C

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and

Keros Therapeutics  KROS reshaped its financial profile in 2025 by pairing a major licensing transac

KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward

JPMorgan Chase and Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ: KROS) by 260

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?

Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 pha

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

Upgrades

  On Thursday, 216 stocks hit new 52-week lows.

  On Tuesday, 951 companies hit new 52-week lows.

Gainers

Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company sa

Gainers Puhui Wealth Investment Management Co., Ltd. (NASDAQ: PHCF) rose 49% to $3.65 in pre-mar

    On Friday morning, 155 companies achieved new lows for the year.

  Before 10 a.m. ET on Tuesday, 172 companies hit new 52-week highs.

  On Monday morning, 204 companies hit new 52-week highs.

  This morning 180 companies set new 52-week highs.